Join Growin Stock Community!

Inotiv, inc.NOTV.US Overview

US StockHealthcare
(No presentation for NOTV)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NOTV AI Insights

NOTV Overall Performance

NOTV AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NOTV Recent Performance

5.95%

Inotiv, inc.

0.05%

Avg of Sector

-0.31%

S&P500

NOTV PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NOTV Key Information

NOTV Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NOTV Profile

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

Price of NOTV

NOTV FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NOTV Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.02
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.02
PB Ratio
0.09
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
23.49%
Net Margin
-13.50%
Revenue Growth (YoY)
8.19%
Profit Growth (YoY)
17.54%
3-Year Revenue Growth
-0.51%
3-Year Profit Growth
4.59%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.02
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.02
PB Ratio
0.09
Price-to-FCF
-
Gross Margin
23.49%
Net Margin
-13.50%
Revenue Growth (YoY)
8.19%
Profit Growth (YoY)
17.54%
3-Year Revenue Growth
-0.51%
3-Year Profit Growth
4.59%

  • When is NOTV's latest earnings report released?

    The most recent financial report for Inotiv, inc. (NOTV) covers the period of 2026Q1 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NOTV's short-term business performance and financial health. For the latest updates on NOTV's earnings releases, visit this page regularly.

  • What is the operating profit of NOTV?

    According to the latest financial report, Inotiv, inc. (NOTV) reported an Operating Profit of -16.55M with an Operating Margin of -13.69% this period, representing a decline of 6.75% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is NOTV's revenue growth?

    In the latest financial report, Inotiv, inc. (NOTV) announced revenue of 120.88M, with a Year-Over-Year growth rate of 0.84%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does NOTV have?

    As of the end of the reporting period, Inotiv, inc. (NOTV) had total debt of 473.16M, with a debt ratio of 0.64. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NOTV have?

    At the end of the period, Inotiv, inc. (NOTV) held Total Cash and Cash Equivalents of 12.73M, accounting for 0.02 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does NOTV go with three margins increasing?

    In the latest report, Inotiv, inc. (NOTV) did not achieve the “three margins increasing” benchmark, with a gross margin of 20.5%%, operating margin of -13.69%%, and net margin of -23.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NOTV's profit trajectory and future growth potential.

  • Is NOTV's EPS continuing to grow?

    According to the past four quarterly reports, Inotiv, inc. (NOTV)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.83. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NOTV?

    Inotiv, inc. (NOTV)'s Free Cash Flow (FCF) for the period is -10.61M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 18.5% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of NOTV?

    The latest valuation data shows Inotiv, inc. (NOTV) has a Price-To-Earnings (PE) ratio of -0.18 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.